strategic governance
-
Goodwood Nominates Directors for Cosciens Biopharma’s Annual Shareholder Meeting
COSCIENS Biopharma faces activist pressure as investors Goodwood Fund and Puccetti Funds Management nominate six board directors, signaling a push for strategic changes. The firm, known for plant-based innovations in skincare (e.g., Aveeno’s oat compounds) and diagnostics like macimorelin, is evaluating the proposal amid scrutiny over its clinical trial pace, particularly for its cholesterol drug candidate. Balancing cosmeceutical growth with pharmaceutical ambitions, COSCIENS confronts investor demands for accelerated commercialization and governance reforms. Challenges include trial uncertainties for its growth hormone diagnostic and market pressures, with leadership decisions likely to shape its trajectory in competitive biopharma markets.
